1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow ANCA Associated Vasculitis: new trials by email Literature Review of ANCA Associated Vasculitis trials Research Report on ANCA Associated Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PR3-AAV Resilient Remission or PRRR Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Terminated | Mayo Clinic | 6 | 2023-06-30 | 2026-05-06 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Granulomatosis with Polyangiitis (1) · Microscopic Polyangiitis (1)
Autoimmune Diseases (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebral Small Vessel Diseases (1) · Cerebrovascular Disorders (1) · Immune System Diseases (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Nervous System Diseases (1) · Respiratory Tract Diseases (1) · Skin Diseases (1) · Skin Diseases, Vascular (1) · Skin and Connective Tissue Diseases (1) · Systemic Vasculitis (1)
Rituximab (1) · obinutuzumab (1)
Mayo Clinic (1)
United States (1)